This year, we have promoted projects of high scientific impact that strengthen our leadership in clinical research. Highlights include the AELIX‑003 study in HIV, which has demonstrated the potential of a therapeutic vaccine to improve viral control without antiretroviral treatment; the COCOS trial in long covid, which explores new therapeutic options for neurocognitive symptoms; and BREAKFREE‑SY, an international project to advance the diagnosis and control of congenital syphilis, funded by an ERC Consolidator.
In addition, we have consolidated relevant advances in global health, such as the first European protocol for screening and treatment of female genital schistosomiasis, which already shows clear improvements in patients’ health.
At the same time, we have launched projects that may transform clinical practice, such as the COVID KIDNEY study, which investigates whether kidney transplants can be safely performed in patients with asymptomatic or mild covid‑19. We have also expanded research into multidrug‑resistant bacteria in aquatic environments and severe infections, strengthening the One Health approach and microbiological surveillance.
This set of studies reflects a year of solid, multidisciplinary progress focused on generating real solutions for people.